register

News & Trends - MedTech & Diagnostics

Breaking new ground in the application of microbiome testing

Health Industry Hub | March 6, 2023 |

MedTech News: Australia’s precision microbiome company has launched its next generation human gut microbiome testing product to healthcare professionals, under a new brand.

A core component of Microba’s strategy is to leverage the company’s world-leading technology and capability to advance the clinical application of microbiome testing to become embedded as a routine part of health and disease management.

Microba Chief Executive Officer, Dr Luke Reid, said “The new MetaXplore test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting. We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”

The new MetaXplore range provides diagnostic gastrointestinal health testing together with metagenomic-driven gut microbiome analysis to deliver comprehensive gastrointestinal testing solutions for healthcare professionals. The MetaXplore test range has been brought to market under a new brand called Co-Biome.

Microba’s Chief Scientific Officer, A/Professor Lutz Krause, said “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting. This test range is expected to significantly expand the total addressable market for Microba’s testing products.”

Sonic Healthcare invested $17.83 million to acquire a 19.99% equity and agreed initial terms for a strategic partnership to deliver Microba’s microbiome testing technology into Australia, Germany, United Kingdom, Switzerland, United States, New Zealand and Belgium.

A major catalyst for the sector occurred with the first FDA approval of a live microbiome drug received by Ferring Pharmaceuticals. A second approval is expected next quarter for Seres Therapeutics. These approvals demonstrate a clear path to market for microbiome drugs, an important catalyst for further investment into the sector.

Dr Reid added “With progress into the clinic with MAP 315 [for the treatment of inflammatory bowel disease] and Microba’s growing intellectual property portfolio we are in a strong position to advance the company’s pipeline towards out-licensing deals”

The test range through next-gen Co-Biome can be accessed in Australia through a healthcare professional, and is expected to be rolled out through Microba’s growing international distribution partner network.

Microba was formed in 2017 based on intellectual property acquired from the University of Queensland. The company launched its first product, Microba Insight, in Australia in July 2018.

Reimagining healthcare across the entire patient journey: Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change in healthcare.

The content on Health Industry Hub is copyright protected and can only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - Pharmaceuticals

Is the government is gearing up to release the long-awaited response to The New Frontier report?

Government’s long-awaited response to The New Frontier report unveiled after two-year wait

Health Industry Hub | December 1, 2023 |

Pharma News: The Albanese Government has tabled its response to the House of Reps inquiry and The New Frontier report […]

More


News & Trends - Pharmaceuticals

Gilead welcomes HIV Taskforce report and celebrates the 'unsung heroes'

Gilead welcomes HIV Taskforce report and celebrates the ‘unsung heroes’

Health Industry Hub | December 1, 2023 |

Pharma News: On World AIDS Day, the National Association of People with HIV Australia (NAPWHA) and Gilead Sciences Australia have […]

More


News & Trends - Pharmaceuticals

AbbVie secures PBS listing of first therapy for Crohn's disease in seven years

AbbVie secures PBS listing of first therapy for Crohn’s disease in seven years

Health Industry Hub | December 1, 2023 |

Pharma News: AbbVie’s Rinvoq (upadacitinib), a once-daily tablet, has been officially listed on the Pharmaceutical Benefits Scheme (PBS) for adult […]

More


ESG

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

New report calls on policy integration of sustainability in medical device and pharmaceutical registrations and funding

Health Industry Hub | November 30, 2023 |

ESG: Increasing pressures from diverse stakeholder groups, spanning policymakers, investors, customers, and employees, have elevated Environmental, Social, and Governance (ESG) […]

More


This content is copyright protected. Please subscribe to gain access.